ERBB2 and breast cancer: Similar models can be used in the case of HER2+ BC, specifically by modeling the presence of impaired receptors and overexpression of certain proteins, peptides, or cytokines (e.g., MUC4, NmU, TGF-β) which can give quantitative insights into the mechanism related to drug resistance development.